VEGFA and hepatocellular carcinoma: Another study proved that YY1 plays an important role in angiogenesis and bevacizumab resistance by inducing VEGFA transcriptional activity and expression, and YY1 may be a potential molecular therapeutic target for anti-angiogenic therapy in HCC (46).